The Taibo? Sildenafil Citrate Orally Disintegrating Tablets (50mg), which is our company's new dosage form and deemed to have passed the consistency evaluation, was recently approved for marketing.
MoreOn April 28, 2011, C&O announced that it has been authorized by Shionogi & Co., Ltd., a Japanese pharmaceutical company, to be the exclusive distributor of Flumarin?, an antibiotic of oxacephalosporins for injection, in China.
MoreIn March 2011, the high standard edaravone raw materials and injection developed by C&O was approved by SFDA. Edaravone is a neuroprotective agent, used to improve neurological symptoms, activities of daily living and functional impairment due to acu
MoreSumitomo became the strategic shareholder with shareholding of 29% held in C&O. C&O Board of Directors has been restructured and Sumitomo Corporation will appoint three directors to the C&O Board.
MoreThe Chinese government has recently included four new drug projects being developed by C&O in the major scientific and technological projects for “major new drug initiation”, the first program established by the Chinese government in the 11th Five-Ye
More
Address5/F, Jihao Building, 1086 Shennan East Road, Luohu District, Shenzhen
Adverse drug reactions / Event feedback hotline025-6816 1304
Adverse drug reactions / Event feedback mailGVP@changao.com
Official WeChat account 
Mobile page